ClinicalTrials.gg
CompletedNCT05540626Updated Oct 21, 2026

RWE Study Utilizing the Cala Trio Device in Patients With Essential Tremor

An interventional study of Cala Trio in Essential Tremor, sponsored by Cala Health, Inc.. Completed at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Cala Health, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Mar 2024, 2 years 8 months ago, and no results have been posted to the registry.
  • Registered 1 year 4 months after the study started (first participant enrolled Apr 2021, registered Sep 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
276
Allocation
Randomized
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 146 studies in Essential Tremor with a site in United States — 40 open to participants now, 46 under way, 1 of them phase 3. Essential Tremor · United States.

Enrollment
5th of 104
276 · median 30
Started
2021
with 11 others
No phase
60 of 146
22 open now
Registered
119th of 146
by date
Lead sponsor
5 of 146
Cala Health, Inc.

Among the 146 studies in Essential Tremor with a site in United States, this one is the 5th largest by enrollment of the 104 interventional ones that give a count, is one of 12 that started in 2021, is one of 60 with no phase, and was the 119th registered.

Essential Tremor

272 studies on the registry are indexed under Essential Tremor; 75 are open to participants now.

Browse Essential Tremor studies →

Open to participants now

40 of the 146 studies in Essential Tremor with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Essential Tremor studies recruiting now, 32 (52%) set no upper age limit and 5 (8%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in Essential Tremor with a site in United States, or all of them as a file.
02

Study summary

The study objective is to evaluate hand tremor relief in the treated hand following stimulation with the Cala Trio Device in adults with essential tremor, and healthcare resource utilization and total healthcare costs over a 12-month period.

Read the detailed description

This is a prospective, randomized, dual arm, pragmatic trial in a real-world setting to evaluate the effectiveness and health economics outcomes of the Cala Trio device in reducing hand tremor and improving quality of life as measured by the Bain and Findley Activities of Daily Living (ADL) score relevant to the stimulated upper limb. Healthcare resources utilization and total all-cause healthcare will also be evaluated. The study will recruit approximately 300 patients: 150 in the intervention arm (Cala Trio device)and 150 patients in the standard of care (SOC) arm. Subjects will be randomized to either the intervention arm or the standard of care arm (1:1).Subjects in the SOC arm will be asked to measure their tremor severity by doing daily postural holds with the Cala Trio device without actual stimulation. Subjects in the intervention arm will wear the device at home for a period of 12 months, during which they will deliver 40 min stimulation sessions, which can be started and stopped on demand. After the first month, the subjects who were randomized to the SOC arm will cross over to the intervention arm.

03

Conditions studied

  • Essential Tremor

Browse trials for

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥22years
  • Aetna commercial fully insured OR Medicare Advantage population (inclusion of Medicare is contingent upon additional internal approvals)
  • Two ICD claims for ET, at least seven days apart, in the last three years OR one ICD claim for ET followed by at least one dispensed pharmaceutical treatment for ET
  • to standard pharmacological therapy (Asthma, , 1stor 2nddegree heart block) OR indicator of poor pharmacological acceptability as evidenced by drug switching behaviors OR indicator of drug resistance as evidenced by the use of drug therapies including Clozapine, Mirtazapine, Gabapentin, Topiramate, Clonazepam or Alprazolam
  • Willing and able to provide to participate in the study
  • Willing and able to follow study protocol requirements
  • Patients with PCP or neurologist provider encounter in past 18months

Exclusion criteria

Exclusion Criteria:

  • ICD-10 evidence of a pacemaker or defibrillator or a procedure code indicating pacemaker implantation, electrode renewal or calibration
  • ICD-10 evidence of a deep brain stimulator or a procedure code indicating DBS implantation
  • CPT/HCPCS evidence of thalamotomy, gamma-knife radio surgical thalamotomy
  • NDC and CPT evidence of botulinum toxin the last 6 months as therapeutic injection in the upper limb
  • Pregnant during the enrollment period
  • Evidence of Parkinson's Disease
  • Evidence of epilepsy
  • Formal diagnosis of hypothyroidism and treatment
  • Formal diagnosis of hyperthyroidism without evidence of treatment
  • Formal diagnosis of dementia
  • Evidence of Treatment with thyroid hormone supplements (2 Rx claims 28 or more days apart) or evidence of hyperthyroidism (2+ claims, 28 days or more apart)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
276 participants (actual)

Study arms

  • No intervention
    Standard of Care Arm

    Baseline tremor power without stimulation (SOC arm) over the first month of the study. Subjects in the SOC arm will be asked to measure their tremor severity by doing daily postural holds with the Cala Trio device without actual stimulation.

  • Experimental
    Intervention with the Cala Trio device (CTD) arm

    Tremor power after stimulation with Cala Trio. Subjects in the intervention arm will wear the device at home for a period of 12 months, during which they will deliver 40 min stimulation sessions, which can be started and stopped on demand.

    Device: Cala Trio

Interventions

  • DeviceCala Trio

    transcutaneous afferent patterned stimulation (TAPS)

06

What researchers measure

Primary outcomes

  1. Change in tremor power

    Difference in tremor power after stimulation with Cala Trio (treated arm) and baseline tremor power without stimulation (SOC arm) over the first month of the study. Prior to and immediately after each of the first 40 stimulation sessions and every 7th session thereafter, the Cala Trio will direct the patient to perform postural hold tremor tasks to measure tremor power pre and post stimulation. The SOC arm will perform a tremor measurement only, without any stimulation sessions, for 1 month.

    Time frame: 1 Month

Secondary outcomes

  1. Bain & Findley Activities of Daily Living (BF-ADL) scale subset score

    BF-ADL subset score relevant to the stimulated upper limb. The subset score is the sum of 8 rated tasks. Each task is rated 1 to 4, where a higher score indicates more severe tremor. Minimum subset score = 8; Maximum subset score = 32. Improvements in BF-ADL scores will be measured from baseline over the 12 months study duration.

    Time frame: 12 Months

  2. Tremor power improvement ratio (TPIR)

    TPIR is defined as the ratio of pre- to post-stimulation tremor power. Per-patient median TPIR over first, second, third, and fourth quarters of the study (i.e., months 1 - 3, 4 - 6, etc.) will be assessed.

    Time frame: 12 Months

07

Study locations

1 site
  • Cala Health
    San Mateo, California 94404, United States
08

References and documents

Publications

  • Brillman S, Khemani P, Isaacson SH, Pahwa R, Deshpande R, Zraick V, Rajagopal A, Khosla D, Rosenbluth KH. Non-Invasive Transcutaneous Afferent Patterned Stimulation Therapy Offers Action Tremor Relief in Parkinson's Disease. Tremor Other Hyperkinet Mov (N Y). 2023 Aug 23;13:25. doi: 10.5334/tohm.762. eCollection 2023. PubMed 37637850 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Mar 2024, 34 months.

Of 95 interventional studies with no phase under Essential Tremor, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 93. This study's 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2022
First posted
Sep 14, 2022
StartActual
Apr 8, 2021
Primary completionActual
Mar 1, 2024
CompletionActual
Mar 1, 2024
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 37637850 ↗
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 37637850 ↗
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05540626
Lead sponsor
Cala Health, Inc.
Collaborators
CVS Healthspire Life Sciences Solutions
Responsible party
Sponsor
First posted
Sep 14, 2022
Start date
Apr 8, 2021
Primary completion
Mar 1, 2024
Completion
Mar 1, 2024
Last update
Oct 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion